Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 7/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607628 | 1.00 | PBK (0.42) | PBKPARP1BRD4ATAD2MAPK1 | |
| SCHEMBL3600250 | 1.00 | PBK (0.42) | PBKPARP1BRD4ATAD2MAPK1 | |
| SCHEMBL3605993 | 0.93 | MAPK1 (0.46) | PBKPARP1MAPK1OPRK1TOP2A | |
| SCHEMBL3605989 | 0.93 | MAPK1 (0.46) | PBKPARP1MAPK1OPRK1TOP2A | |
| SCHEMBL3614136 | 0.93 | MAPK1 (0.46) | PBKPARP1MAPK1OPRK1TOP2A | |
| SCHEMBL3599045 | 0.92 | PBK (0.42) | PBKPARP1MAPK1OPRK1 | |
| SCHEMBL3606194 | 0.78 | PBK (0.39) | PBKHDAC4 | |
| SCHEMBL3597760 | 0.78 | PBK (0.39) | PBKHDAC4 | |
| SCHEMBL3597756 | 0.78 | PBK (0.39) | PBKHDAC4 | |
| SCHEMBL3611678 | 0.76 | PBK (0.47) | PBKHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | PBK 2463/4885PARP1 156/4885BRD4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.